应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
WXXWY 药明生物ADR
休市中 08-16 16:00:00 EDT 延时
资讯
新帖
简况
药明生物与Medigene达成研究合作推进通用型TCR介导的TCE疗法研究
美通社 · 08-08
药明生物与Medigene达成研究合作推进通用型TCR介导的TCE疗法研究
药明生物四个生产厂和生物药安全检测中心的十个生物药项目再次获得欧洲药品管理局GMP认证
美通社 · 08-01
药明生物四个生产厂和生物药安全检测中心的十个生物药项目再次获得欧洲药品管理局GMP认证
药明生物连续四年入选富时社会责任指数系列
美通社 · 07-10
药明生物连续四年入选富时社会责任指数系列
药明生物发布2023年ESG报告 彰显对可持续发展的坚定承诺
美通社 · 04-30
药明生物发布2023年ESG报告 彰显对可持续发展的坚定承诺
药明生物2023年业绩稳健增长
美通社 · 03-26
药明生物2023年业绩稳健增长
药明生物凭借全球水安全管理领导力荣获CDP A级评分
美通社 · 03-22
药明生物凭借全球水安全管理领导力荣获CDP A级评分
药明生物荣登2023 CDP气候变化榜单,彰显卓越环境领导力
美通社 · 03-05
药明生物荣登2023 CDP气候变化榜单,彰显卓越环境领导力
药明生物再度蝉联晨星Sustainalytics 2024年“ESG行业最高评级”及“ESG区域最高评级”企业
美通社 · 02-21
药明生物再度蝉联晨星Sustainalytics 2024年“ESG行业最高评级”及“ESG区域最高评级”企业
暂无数据
公司概况
公司名称:
药明生物ADR
所属市场:
PINK
上市日期:
--
主营业务:
药明生物技术有限公司是一家主要从事向生物制剂行业的客户提供就生物发现、开发及生产的端到端解决方案及服务的投资控股公司。该公司主要通过两个分部运营其业务。生物药分部主要从事提供生物药的发现、开发和生产。药明合联(XDC)分部主要从事为抗体偶联药物(ADCs)及各种生物偶联药物提供合同研究、开发及生产组织(CRDMO)服务。该公司主要在国内和国外市场开展其业务。
发行价格:
--
{"stockData":{"symbol":"WXXWY","market":"US","secType":"STK","nameCN":"药明生物ADR","latestPrice":2.98,"timestamp":1723838400000,"preClose":2.87,"halted":0,"volume":20655,"delay":15,"floatShares":1776230732,"shares":2075818699,"eps":0.217931,"marketStatus":"休市中","marketStatusCode":7,"change":0.11,"latestTime":"08-16 16:00:00 EDT 延时","open":2.9,"high":2.98,"low":2.9,"amount":60920.61099999999,"amplitude":0.027875,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.217931,"exchange":"PINK","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1724054400000},"adr":0,"adjPreClose":2.87,"adrRate":2,"volumeRatio":0.6259584084649346},"requestUrl":"/m/hq/s/WXXWY/tweets","defaultTab":"tweets","newsList":[{"id":"2457531363","title":"药明生物与Medigene达成研究合作推进通用型TCR介导的TCE疗法研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2457531363","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457531363?lang=zh_cn&edition=full","pubTime":"2024-08-08 16:11","pubTimestamp":1723104660,"startTime":"0","endTime":"0","summary":"该合作将充分结合Medigene在T细胞受体生成和表征研究领域的领先优势,以及药明生物独特的CD3抗体、T细胞衔接子技术平台以及专利双抗技术平台WuXiBody 该合作为期三年,可涉及多个TCR项目 中国上海和德国慕尼黑2024年8月8日 /美通社/ -- 全球领先的合同研究、开发和生产服务公司药明生物今日宣布与TCR肿瘤免疫治疗生物技术公司Medigene AG达成一项为期三年、覆盖多个靶点的战略研究服务合作,双方将设计并研究用于治疗难治性肿瘤的TCR介导TCE疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4478609_ZH78609_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["WXXWY","LU0588546209.SGD","LU0359202008.SGD","BK1576","LU0516422366.SGD","LU0708995583.HKD","LU0823426308.USD","BK4121","LU0327786744.USD","BK4571","LU0348825331.USD","LU0307460666.USD","LU0456846285.SGD","SG9999002562.SGD","BK4565","LU0456827905.SGD","LU0572944931.SGD","02269","BK4563","LU0326950275.SGD","LU0348735423.USD","LU0039217434.USD","LU0823426480.USD","LU1688375341.USD","IE00B12V2V27.USD","BK4509","LU0516422440.USD","LU0140636845.USD","BK1610","IE00BYQNZ168.SGD","IE00BYTNYN87.SGD","ESG","IE00B0JY6N72.USD","BK4535","LU0856984785.SGD","LU1242518857.USD","BK1589","LU0819121731.USD","LU0043850808.USD","LU0516423091.SGD","SG9999011746.SGD","LU0516422952.EUR","LU1880383366.USD","LU1720050803.USD","LU1242518931.SGD","LU0417516902.SGD","TME","LU2039709279.SGD","BK4552","01698"],"gpt_icon":0},{"id":"2456753381","title":"药明生物四个生产厂和生物药安全检测中心的十个生物药项目再次获得欧洲药品管理局GMP认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2456753381","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456753381?lang=zh_cn&edition=full","pubTime":"2024-08-01 15:00","pubTimestamp":1722495600,"startTime":"0","endTime":"0","summary":"此外,药明生物苏州检测中心也再次获得EMA针对十款创新药品的GMP认证,其中包括前述八款创新药。目前,药明生物的全球生产网络已有十五个获药品监管机构认证的生物药原液和制剂生产厂。截至2023年12月底,药明生物帮助客户研发和生产的综合项目高达698个,其中包括24个商业化生产项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4474528_ZH74528_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1141","LU0140636845.USD","LU1242518857.USD","02269","SG9999002562.SGD","SG9999002463.SGD","LU1688375341.USD","LU0327786744.USD","LU0516423091.SGD","BK1610","LU0708995583.HKD","LU1720050803.USD","LU0320764599.SGD","LU0516423174.USD","LU0348825331.USD","ESG","LU0359202008.SGD","LU0456827905.SGD","BK1589","LU0051755006.USD","LU1794554557.SGD","LU0417516902.SGD","LU0043850808.USD","LU0856984785.SGD","LU0039217434.USD","LU0572944931.SGD","LU0307460666.USD","LU0456846285.SGD","BK4121","LU0819121731.USD","LU0823426308.USD","LU0326950275.SGD","LU0348735423.USD","BK1576","LU0359201612.USD","LU0052750758.USD","LU0588546209.SGD","LU0979878070.USD","LU0823426480.USD","LU0516422366.SGD","LU1242518931.SGD","LU1880383366.USD","LU2039709279.SGD","IE00B0JY6N72.USD","BK1521","WXXWY","LU0516422952.EUR","LU0417516738.SGD","LU0181495838.USD","LU0516422440.USD"],"gpt_icon":0},{"id":"2450830699","title":"药明生物连续四年入选富时社会责任指数系列","url":"https://stock-news.laohu8.com/highlight/detail?id=2450830699","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450830699?lang=zh_cn&edition=full","pubTime":"2024-07-10 13:30","pubTimestamp":1720589400,"startTime":"0","endTime":"0","summary":"上海2024年7月10日 /美通社/ -- 全球领先的合同研究、开发和生产CRDMO服务公司药明生物宣布,公司连续第四年入选\"富时社会责任指数系列\" ,充分彰显了公司在可持续发展领域的卓越表现。过去几年,药明生物富时罗素ESG评分的总分和各议题分均有显著提升。2024年,公司ESG评分排名行业前7%。药明生物首席执行官,ESG委员会主席陈智胜博士表示:\"我们非常荣幸能够再次被纳入富时社会责任指数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4458212_ZH58212_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0823426480.USD","LU0823426308.USD","LU0181495838.USD","LU1794554557.SGD","LU0516422440.USD","02269","LU0359201612.USD","ESG","LU0979878070.USD","LU0516422366.SGD","LU0051755006.USD","SG9999002562.SGD","LU0819121731.USD","BK1589","WXXWY","LU1242518931.SGD","LU0327786744.USD","LU0572944931.SGD","LU0456827905.SGD","IE00B0JY6N72.USD","LU0516423091.SGD","LU0456846285.SGD","LU0417516738.SGD","LU0516422952.EUR","LU0417516902.SGD","LU0708995583.HKD","LU1720050803.USD","LU1242518857.USD","LU0359202008.SGD","LU0348735423.USD","LU1688375341.USD","LU2039709279.SGD","LU0043850808.USD","LU0326950275.SGD","LU0307460666.USD","BK1521","LU0856984785.SGD","LU0052750758.USD","LU1880383366.USD","LU0516423174.USD","BK1576","LU0140636845.USD","BK4121","SG9999002463.SGD","BK1610","LU0348825331.USD","LU0320764599.SGD","LU0039217434.USD","BK1141","LU0588546209.SGD"],"gpt_icon":0},{"id":"2431738220","title":"药明生物发布2023年ESG报告 彰显对可持续发展的坚定承诺","url":"https://stock-news.laohu8.com/highlight/detail?id=2431738220","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2431738220?lang=zh_cn&edition=full","pubTime":"2024-04-30 10:55","pubTimestamp":1714445700,"startTime":"0","endTime":"0","summary":"公司获主流 ESG 评级机构广泛认可,保持行业ESG领导地位。药明生物的ESG战略始终以公司愿景和使命为指引,并充分融入公司的全球业务运营中。2023年,药明生物加入联合国全球契约组织,履行其对企业和社会可持续发展的承诺。\" 药明生物2023年度ESG报告围绕员工、全球合作伙伴、社区和环境等重大议题,全面、透明地阐述了公司ESG战略及其卓越进展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4401001_ZH01001_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0979878070.USD","LU0823426308.USD","LU0456827905.SGD","LU0348735423.USD","LU0039217434.USD","LU0181495838.USD","LU0348825331.USD","LU0708995583.HKD","LU0516423091.SGD","IE00B0JY6N72.USD","LU0819121731.USD","LU0823426480.USD","LU0051755006.USD","WXXWY","LU0327786744.USD","LU0052750758.USD","LU0516422440.USD","LU0359202008.SGD","LU0417516738.SGD","SG9999002562.SGD","LU2039709279.SGD","ESG","LU0516423174.USD","SG9999002463.SGD","LU0456846285.SGD","LU0359201612.USD","LU1880383366.USD","BK1576","LU1720050803.USD","02269","BK1610","LU0307460666.USD","LU0856984785.SGD","LU1794554557.SGD","LU0516422366.SGD","LU0516422952.EUR","LU1242518857.USD","LU0320764599.SGD","LU0588546209.SGD","BK4121","LU0572944931.SGD","BK1521","BK1589","LU1242518931.SGD","BK1141","LU1688375341.USD","LU0326950275.SGD","LU0417516902.SGD","LU0043850808.USD","LU0140636845.USD"],"gpt_icon":0},{"id":"2422238610","title":"药明生物2023年业绩稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2422238610","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2422238610?lang=zh_cn&edition=full","pubTime":"2024-03-26 22:57","pubTimestamp":1711465020,"startTime":"0","endTime":"0","summary":"2023年业务亮点 尽管新冠疫情后面临严峻的宏观环境挑战,集团凭借独特的CRDMO商业模式和成功实施\"跟随并赢得分子\"战略,依然保持业务稳健增长。截至2023年12月31日,集团包括未完成服务订单和里程碑付款在内的未完成订单总额达206亿美元。临床后期和商业化生产收益增长至人民币77.3亿元,占2023年总收益的45.4%,延续集团临床后期和商业化生产业务加速增长势头。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4371111_ZH71111_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["ADC","BK4121","LU1242518857.USD","LU0289961442.SGD","LU0307460666.USD","LU0572944931.SGD","GSK.UK","LU0417516902.SGD","LU0175139822.USD","LU0348735423.USD","LU1720050803.USD","LU2095319765.USD","D","IE00B0JY6N72.USD","LU0326950275.SGD","BK4231","LU0348825331.USD","LU1804176565.USD","LU2210149790.SGD","VLP","WBS","GSK","BK4007","LU0516422952.EUR","LU0823426308.USD","MSCI","LU2039709279.SGD","LU2210150020.SGD","BK1589","BK4532","ESG","SG9999002562.SGD","BK4232","M","LU2265009873.SGD","R","LU0823426480.USD","LU0516422440.USD","LU1688375341.USD","LU0511384066.AUD","02269","BK4080","BK1521","WXXWY","BNTX","LU0043850808.USD","BK4548","LU0856984785.SGD","BK4535"],"gpt_icon":0},{"id":"2421862124","title":"药明生物凭借全球水安全管理领导力荣获CDP A级评分","url":"https://stock-news.laohu8.com/highlight/detail?id=2421862124","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2421862124?lang=zh_cn&edition=full","pubTime":"2024-03-22 17:26","pubTimestamp":1711099560,"startTime":"0","endTime":"0","summary":"根据2023年CDP水安全调查问卷报告,药明生物从23000多家企业中脱颖而出,在该议题中获得A级评分,名列获此殊荣企业的前2%。药明生物首席执行官、ESG委员会主席陈智胜博士表示:\"药明生物始终将可持续发展视为全球业务发展的战略基石,我们深感荣耀能够入选CDP 2023年水安全管理A级榜单。\" 2023 年,药明生物在水资源管理领域表现卓越。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4368383_ZH68383_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0051755006.USD","LU0417516738.SGD","LU0417516902.SGD","LU0588546209.SGD","02269","LU0043850808.USD","LU0359202008.SGD","LU1688375341.USD","LU0823426308.USD","LU0979878070.USD","WXXWY","LU0181495838.USD","LU0140636845.USD","LU0708995583.HKD","SG9999002463.SGD","LU0307460666.USD","LU0823426480.USD","LU0359201612.USD","LU0516423174.USD","LU2039709279.SGD","LU0819121731.USD","LU0348735423.USD","LU0516423091.SGD","LU0572944931.SGD","LU0516422952.EUR","IE00B0JY6N72.USD","LU0052750758.USD","LU1720050803.USD","LU0320764599.SGD","SG9999002562.SGD","BK1610","LU1794554557.SGD","BK1576","LU0326950275.SGD","CDP","LU0456827905.SGD","LU0456846285.SGD","LU0516422366.SGD","BK4223","LU1242518857.USD","LU0856984785.SGD","BK1521","LU0516422440.USD","LU1880383366.USD","BK4121","LU0348825331.USD","BK1589","LU0327786744.USD","BK1141","LU1242518931.SGD"],"gpt_icon":0},{"id":"2417462647","title":"药明生物荣登2023 CDP气候变化榜单,彰显卓越环境领导力","url":"https://stock-news.laohu8.com/highlight/detail?id=2417462647","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2417462647?lang=zh_cn&edition=full","pubTime":"2024-03-05 17:30","pubTimestamp":1709631000,"startTime":"0","endTime":"0","summary":"CDP负责管理全球企业、城市、州和地区的环境信息披露系统。2023年共有超23000家公司参与CDP评级,披露其气候变化应对、森林保护和水资源管理数据。药明生物首席执行官、ESG委员会主席陈智胜博士表示:\"入选CDP领导力级别榜单,我们倍感荣幸,这印证了药明生物应对气候变化的承诺和行动力。\" 2023年,药明生物在应对气候变化方面取得了丰硕成果。截至2023年12月底,药明生物帮助客户研发和生产的综合项目高达698个,其中包括24个商业化生产项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4352902_ZH52902_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["WXXWY","LU0588546209.SGD","SG9999002463.SGD","LU0359202008.SGD","BK1576","LU0516422366.SGD","LU0708995583.HKD","LU0181495838.USD","LU0823426308.USD","BK4121","BK1521","LU0327786744.USD","LU0348825331.USD","LU0307460666.USD","LU0456846285.SGD","SG9999002562.SGD","BK4223","CDP","LU0456827905.SGD","LU0572944931.SGD","02269","LU0326950275.SGD","LU0359201612.USD","LU0348735423.USD","LU0039217434.USD","LU0823426480.USD","LU1688375341.USD","LU0417516738.SGD","LU0516422440.USD","LU0140636845.USD","LU0051755006.USD","BK1610","LU1794554557.SGD","IE00B0JY6N72.USD","BK1141","LU0856984785.SGD","LU1242518857.USD","BK1589","LU0516423174.USD","LU0819121731.USD","LU0043850808.USD","LU0516423091.SGD","LU0516422952.EUR","LU1880383366.USD","LU0979878070.USD","LU1720050803.USD","LU1242518931.SGD","LU0417516902.SGD","LU2039709279.SGD","LU0320764599.SGD"],"gpt_icon":0},{"id":"2413468891","title":"药明生物再度蝉联晨星Sustainalytics 2024年“ESG行业最高评级”及“ESG区域最高评级”企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2413468891","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2413468891?lang=zh_cn&edition=full","pubTime":"2024-02-21 10:13","pubTimestamp":1708481580,"startTime":"0","endTime":"0","summary":"Sustainalytics是一家提供ESG数据、研究和评级的权威公司,为全球投资者制定和实施负责任的投资战略。今年,Sustainalytics的ESG评级覆盖了全球42个行业的14000多家公司,并从中评选出在ESG领域取得卓越成就的公司授予\"最高评级\"奖章。药明生物获得了Sustainalytics的高度认可,在制药行业近千家受评企业中位列前2%。关于晨星Sustainalytics Sustainalytics与数百家世界领先的资产管理公司和养老基金合作,将环境、社会和公司治理信息及评估纳入其投资流程。版权所有 2024 晨星Sustainalytics。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4340496_ZH40496_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["WXXWY","02269","ESG"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wuxibiologics.com","stockEarnings":[{"period":"1week","weight":0.0455},{"period":"1month","weight":0.056},{"period":"3month","weight":0.1404},{"period":"6month","weight":0.0218},{"period":"1year","weight":0.2475},{"period":"ytd","weight":0.6829}],"description":"药明生物技术有限公司是一家主要从事向生物制剂行业的客户提供就生物发现、开发及生产的端到端解决方案及服务的投资控股公司。该公司主要通过两个分部运营其业务。生物药分部主要从事提供生物药的发现、开发和生产。药明合联(XDC)分部主要从事为抗体偶联药物(ADCs)及各种生物偶联药物提供合同研究、开发及生产组织(CRDMO)服务。该公司主要在国内和国外市场开展其业务。","exchange":"PINK","name":"药明生物ADR","nameEN":"Wuxi Biologics (Cayman) Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明生物ADR(WXXWY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明生物ADR(WXXWY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明生物ADR,WXXWY,药明生物ADR股票,药明生物ADR股票老虎,药明生物ADR股票老虎国际,药明生物ADR行情,药明生物ADR股票行情,药明生物ADR股价,药明生物ADR股市,药明生物ADR股票价格,药明生物ADR股票交易,药明生物ADR股票购买,药明生物ADR股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明生物ADR(WXXWY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明生物ADR(WXXWY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}